Century Therapeutics (IPSC) Income from Continuing Operations (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Income from Continuing Operations of 90912000.0 for Q1 2026, down 218.75% year-over-year from 76560000.0 in Q1 2025, and down 852.26% quarter-over-quarter from 9547000.0 in Q4 2025.
Century Therapeutics (IPSC) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Income from Continuing Operations for 7 consecutive years, with 90912000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 218.75% year-over-year to 90912000.0; the TTM figure through Mar 2026 stood at 167422000.0 (down 677.04% YoY), while the FY2025 annual figure was 2070000.0, up 101.64% from the prior year.
- Income from Continuing Operations eased to 90912000.0 in Q1 2026 per IPSC's latest filing, from 9547000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 76560000.0 in Q1 2025 and bottomed at 90912000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 28507941.18 across 5 years, with a median of 31682000.0 in 2022.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations soared 372.82% — and 2026, when it plunged 218.75%.
- Century Therapeutics' Income from Continuing Operations stood at 31682000.0 in 2022, then fell by 24.35% to 39398000.0 in 2023, then gained by 9.45% to 35673000.0 in 2024, then soared by 73.24% to 9547000.0 in 2025, then slumped by 852.26% to 90912000.0 in 2026.
- Business Quant data shows IPSC's Income from Continuing Operations at 90912000.0 in Q1 2026, 9547000.0 in Q4 2025, and 34422000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | -90.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -90.36 Mn |
| Mar 31, 2026 | -90.91 Mn |
| Dec 31, 2025 | -9.55 Mn |
| Sep 30, 2025 | -34.42 Mn |
| Jun 30, 2025 | -32.54 Mn |
| Mar 31, 2025 | 76.56 Mn |
| Dec 31, 2024 | -35.67 Mn |
| Sep 30, 2024 | -31.23 Mn |
| Jun 30, 2024 | -31.21 Mn |
| Mar 31, 2024 | -28.06 Mn |
| Dec 31, 2023 | -39.40 Mn |
| Sep 30, 2023 | -32.72 Mn |
| Jun 30, 2023 | -33.29 Mn |
| Mar 31, 2023 | -31.26 Mn |
| Dec 31, 2022 | -31.68 Mn |
| Sep 30, 2022 | -30.75 Mn |
| Jun 30, 2022 | -30.99 Mn |
| Mar 31, 2022 | -37.51 Mn |
| Dec 31, 2021 | -28.15 Mn |
| Sep 30, 2021 | -26.01 Mn |